Madison, WI, October 15, 2008 --(PR.com
)-- Transcreener® ADP2 FP Assay Still Universal. Now More Sensitive.
This "next generation" ADP detection assay offers improved sensitivity and increased flexibility over the original ADP detection assay.
The Transcreener ADP2 FP Assay is a homogenous fluorescence polarization assay that enables the facile detection and screening of established drug targets including protein and lipid kinases as wells as emerging targets such as heat shock proteins and other ATPases. The assay is based on the immunodetection of ADP and allows the screening of diverse enzymes with native and synthetic substrates (or no substrates)-all with the same set of reagents.
· Simple, single-addition endpoint assay
· Excellent signal at < 10% ATP consumption for a broad range of initial ATP concentrations (0.1-1000 uM).
· Ratiometric, red-shifted fluorescence polarization output minimizes signal variability and reduces compound interference, resulting in robust Z’ values ≥0.7 in 384 and 1536-well formats.
· Enables the use of initial velocity enzyme kinetics at or below ATP Km concentrations, which leads to accurate inhibitor potencies and conserved enzyme and substrate costs.
By providing one assay format for many drug targets, the Transcreener platform simplifies high throughput screening and provides a more integrated approach to drug discovery.
For comprehensive data, visit
or contact them at 866.313.7881 or firstname.lastname@example.org